Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL
NCT00187161
Completed
This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymphoblastic leukemia can be delivered in this setting with acceptable toxicity.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
06/03/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Mature B-Cell
Register for Updates
Large Cell Lymphoma Pilot Study III
NCT00187070
Completed
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with hematopoietic stem cell support for children with large cell lymphoma
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/06/2008
Locations: St. Jude Children's Reaearch Hospital, Memphis, Tennessee
Conditions: Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Register for Updates
Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission
NCT00667927
Completed
This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
04/25/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Myeloid Leukemia
Register for Updates
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
NCT00187122
Completed
The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.
Gender:
ALL
Ages:
All
Trial Updated:
04/21/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Lymphoblastic Lymphoma
Register for Updates
Drug Therapy in Lupus Nephropathy
NCT00001212
Completed
Studies have shown that up to 26% of patients with systemic lupus erythematoses nephritis may suffer from membranous lupus nephropathy. The disease is characterized by high levels of protein in the urine and may eventually lead to kidney failure. This study will evaluate the effectiveness and toxic effects of immunosuppressive drug therapy in patients with membranous lupus nephropathy over a 12 month period. The major goal of this therapy is to decrease protein losses and ultimately prevent kid... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/08/2008
Locations: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland
Conditions: Nephrotic Syndrome, Systemic Lupus Erythematosus
Register for Updates
Treatment of Wegener's Granulomatosis With Cyclophosphamide
NCT00001155
Completed
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland
Conditions: Vasculitis, Wegener's Granulomatosis
Register for Updates
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
NCT00001209
Completed
This protocol is designed to test the feasibility of the administration of vincristine, adriamycin and cytoxan, alternating with the newly developed regimen ifosfamide VP-16 as well as the efficacy of this therapy in addition to radiotherapy in producing complete responses and disease-free survival in patients with Ewing's sarcoma, primitive sarcoma of bone, peripheral neuroepithelioma, and soft tissue sarcoma. This will not be a randomized study but will be comparable to the large data base of... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Neuroectodermal Tumor, Primitive, Neuroepithelioma, Osteosarcoma, Sarcoma, Sarcoma, Ewing's
Register for Updates
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
NCT00001384
Completed
This is a pilot feasibility trial of AC (Adriamycin, cyclophosphamide) chemotherapy with G-CSF (filgrastim) followed by infusional Taxol (paclitaxel) as adjuvant treatment for patients with high risk stage II and stage III breast cancer. Cycles will be 14 days in duration. After 3 fourteen day cycles of AC with filgrastim, patients will be treated with 3 fourteen day cycles of 96 hour infusional paclitaxel. The goal of this study will be to assess the toxicity and feasibility of administering do... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
NCT00001498
Completed
Stage III patients may begin therapy prior to or following surgery. Patients with undrainable significant third space fluid collection (e.g., pleural effusions, ascites) are entered directly on Consolidation. Patients receive induction chemotherapy with methotrexate and fluorouracil every 2 weeks for 4 courses. Patients then receive two 3-week courses of consolidation therapy with cyclophosphamide, followed by daily granulocyte colony-stimulating factor until completion of leukapheresis. Patie... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
NCT00040651
Terminated
Scleroderma, or systemic sclerosis (SSc), is a diffuse connective tissue disease characterized by changes in the skin, blood vessels, skeletal muscles, and internal organs. The purpose of this study is to determine the safety and value of self bone marrow transplants after chemotherapy in patients with severe SSc.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/19/2007
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Scleroderma, Systemic Sclerosis
Register for Updates
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
NCT00333008
Unknown
The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2006
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland +1 locations
Conditions: Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Register for Updates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
NCT00131313
Unknown
This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2005
Locations: Northwest Alabama Cancer Center, PC, Muscle Shoals, Alabama +51 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates